920. A Phase 2 Multi-Center, Prospective, Randomized, Double-Blind Study to Assess the Clinical and Antiviral Efficacy and Safety of Nitazoxanide for the Treatment of Norovirus in Hematopoietic Stem Cell and Solid Organ Transplant Recipients
C Boutin(Centre Hospitalier de l’Université de Montréal), Robin K. Avery(Johns Hopkins University), Michael D. Green(University of Michigan), M. Hong Nguyen(University of Pittsburgh), Diana F. Florescu(Office of Infectious Diseases), Michael Angarone(Northwestern University), Ajit P. Limaye(University of Washington), Laurie Keefer(Northwestern University), Steven A. Pergam(Seattle Cancer Care Alliance), Daniel Kaul(University of Michigan), Pearlie P. Chong(The University of Texas Southwestern Medical Center), Michael G. Ison(National Institutes of Health), Marian G. Michaels(University of Pittsburgh), Amna Daud(Northwestern University), Lara Danziger‐Isakov(Cincinnati Children's Hospital Medical Center), Cynthia E. Fisher(University of Washington), Michelle Callegari(Northwestern University), Lisa Clough(University of Kansas Medical Center)
Cited by 2
Related Papers
Development and Validation of the Rome IV Diagnostic Questionnaire for Adults
|Gastroenterology|2016|696
Baboon-to-human liver transplantation
|The Lancet|1993|469
Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients: A Multicenter Cohort Study
|Clinical Infectious Diseases|2012|299
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
|Clinical Infectious Diseases|2021|299
Early impact of COVID-19 on transplant center practices and policies in the United States
|American Journal of Transplantation|2020|244